| Literature DB >> 36033969 |
Jing Zhao1, Guozhou Wang2, Lei Chen2, Simiao Yu2, Wenli Li2.
Abstract
A primary cancer diagnosis has been confirmed as an important risk factor for falls, and the incidence of falls has been shown to be higher in patients who have undergone cancer treatment than in those who have not undergone cancer treatment. Falls during hospitalization increase the medical costs of additional treatment and falls-related mortality. Many falls are preventable and a good understanding of the predictors of falls in this population is needed. However, the risk factors for falls have not yet been identified. The purpose of this review was to identify the risk factors for falls in hospitalized patients with cancer. Eleven English and Chinese electronic databases were searched from their inception to April 2022 and the methodological quality of the included studies was assessed using the Newcastle-Ottawa Quality Assessment Scale. Five studies involving 1237 patients with cancer were included. The meta-analysis identifies eleven risk factors for falls in hospitalized patients with cancer, including age, history of falls, opiates, benzodiazepines, steroids, antipsychotics, sedatives, radiation therapy, chemotherapy, the use of an assistive device and length of hospitalization. Based on the evidence presented in this article, healthcare workers have the capacity to help reduce fall risk through the development of preventive support strategies in this population. Multicenter, prospective studies of patients with cancer should be conducted to further identify and validate their risk factors for falls.Entities:
Keywords: Cancer; Fall risk factors; Inpatient falls; Meta-analysis; Systematic review
Year: 2022 PMID: 36033969 PMCID: PMC9398916 DOI: 10.1016/j.apjon.2022.100107
Source DB: PubMed Journal: Asia Pac J Oncol Nurs ISSN: 2347-5625
Fig. 1Flowchart of the study selection process for inclusion in the meta-analysis.
Characteristics of included studies.
| Author, Year, Country | Patient recruitment | Case/controls | How falls were assessed/ascertained | Study design | Risk factors for falls | Study quality score (NOS) |
|---|---|---|---|---|---|---|
| Jun | Hospitalized patients with cancer | 178/178 | Medical records | Case–control study | history of falls use of an assistive device a high fall scale score on admission a high ECOG score pain fatigue abnormal vital signs on admission surgery radiotherapy benzodiazepines steroids opiates antipsychotic | 7 |
| Vela | Inpatients with hematological malignancy | 59/109 | Incident reporting system | Case–control study | age ≥ 65 leukemia benzodiazepines anticonvulsants corticosteroids antidepressants | 5 |
| Capone | Hospitalized patients with cancer | 143/145 | Event report system | Case–control study | low pain level abnormal gait cancer type metastasis blood product antidepressant antipsychotic | 7 |
| Sophie | In-patients with advanced cancer | 36/162 | Incident report form | Case–control study | delirium neuroleptics | 7 |
| O'Connell | Hospitalized patients with cancer | 34/193 | Medical records | Cohort study | age ECOG scale muscle strength self-rated fatigue score | 6 |
NOS, Newcastle–Ottawa Scale; ECOG: Eastern Cooperative Oncology Group.
Fig. 2Age in the falls group versus the non-falls group.
Fig. 3Female in the falls group versus the non-falls group.
Fig. 4History of falls in the falls group versus the non-falls group.
Fig. 5The use of an assistive device in the falls group versus the non-falls group.
Associated factors of falls in patients with cancer in meta-analysis.
| Risk factors | No. of studies | Cases/controls | Heterogeneity of study design | Model | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Age | 4 | 272/609 | 3.74 (0.72–6.77) | 2.43 | 0.02 | 7.47 | 0.06 | 60 | R | 0.898 |
| Female | 5 | 450/787 | 1.16 (0.91–1.49) | 1.21 | 0.23 | 2.47 | 0.65 | 0 | F | 0.783 |
| Opiates | 4 | 416/594 | 1.72 (1.28–2.33) | 3.54 | 0.0004 | 1.43 | 0.70 | 0 | F | 0.472 |
| Benzodiazepines | 4 | 416/594 | 2.17 (1.59–2.97) | 4.84 | <0.000,01 | 4.10 | 0.25 | 27 | F | 0.377 |
| Antidepressants | 3 | 238/416 | 2.09 (0.94–4.64) | 1.82 | 0.07 | 6.66 | 0.04 | 70 | R | 0.309 |
| Steroids | 4 | 416/594 | 2.89 (1.66–5.03) | 3.75 | 0.0002 | 10.53 | 0.01 | 72 | R | 0.457 |
| Antipsychotics | 3 | 357/485 | 3.12 (2.13–4.56) | 5.87 | <0.000,01 | 2.28 | 0.32 | 12 | F | 0.684 |
| Sedatives | 2 | 179/307 | 2.78 (1.60–4.86) | 3.60 | 0.0003 | 1.02 | 0.31 | 2 | F | NA |
| Dementia | 2 | 179/307 | 2.43 (0.10–57.79) | 0.55 | 0.58 | 4.64 | 0.03 | 78 | R | NA |
| Radiation therapy | 2 | 321/323 | 2.08 (1.41–3.07) | 3.67 | 0.0002 | 0.35 | 0.55 | 0 | F | NA |
| Chemotherapy | 3 | 357/485 | 1.71 (1.14–2.59) | 2.57 | 0.01 | 0.49 | 0.78 | 0 | F | 0.998 |
| Anemia | 2 | 321/323 | 1.41 (0.96–2.06) | 1.76 | 0.08 | 1.93 | 0.16 | 48 | F | NA |
| Use of an assistive device | 2 | 321/323 | 5.93 (1.51–23.23) | 2.55 | 0.01 | 2.88 | 0.09 | 65 | R | NA |
| History of falls | 4 | 414/625 | 4.99 (1.84–13.53) | 3.16 | 0.002 | 6.44 | 0.09 | 53 | R | 0.099 |
| Main oncologic disease (solid tumor) | 3 | 357/485 | 0.50 (0.15–1.70) | 1.11 | 0.27 | 11.12 | 0.004 | 82 | R | 0.970 |
| Metastasis | 2 | 321/323 | 2.67 (0.84–8.50) | 1.66 | 0.10 | 11.71 | 0.0006 | 91 | R | NA |
| Hemoglobin level (g/L) | 2 | 95/271 | −0.50 (-4.11–3.12) | 0.27 | 0.79 | 0.15 | 0.70 | 0 | F | NA |
| Length of hospitalization (days) | 3 | 238/416 | 6.85 (4.65–9.05) | 6.11 | <0.000,01 | 3.69 | 0.16 | 46 | F | 0.893 |
Model: R, random; F, fixed; NA, not available.